Search Results for "Xifaxan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Xifaxan. Results 11 to 17 of 17 total matches.
See also: rifaximin
Expanded Table: Antibiotics for Travelers' Diarrhea (online only)
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
by fever
and/or bloody stools
144.00
Rifaximin – Xifaxan (Salix) 200, 550 mg tabs 200 mg tid x 3 days6 ...
View the Expanded Table: Antibiotics for Travelers' Diarrhea
Treatment of Clostridium Difficile Infection
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011 (Issue 1358)
that rifaximin
(Xifaxan), a non-absorbed rifamycin approved for
treatment of traveler’s diarrhea, might ...
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic virulent strain (NAP1/BI/027). Common risk factors include admission to a healthcare facility, increasing age and severity of underlying illness, gastric acid suppression and exposure to antimicrobials, particularly clindamycin, ampicillin, cephalosporins or fluoroquinolones. Patients who develop CDI while receiving a precipitating antibiotic should have the antibiotic...
Treatment of Clostridium difficile-Associated Disease (CDAD)
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006 (Issue 1247)
for treatment of mild to moderate CDAD.
15
Rifaximin (Xifaxan), a non-absorbed oral antibiotic
approved ...
The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third generation cephalosporins, clindamycin and fluoroquinolones. The emergence in recent years of a new, more toxic epidemic strain (BI/NAP1), possibly related to widespread use of fluoroquinolones, has caused a marked increase in the incidence and severity of C. difficile-associated disease (CDAD).
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
) with the minimally absorbed rifamycin
derivative rifaximin (Xifaxan) is another option.
A meta-analysis of two ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
stool frequency, but do not improve
global IBS symptoms.
Rifaximin (Xifaxan) for 14 days is effective ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
strains of E.
coli.11 It is structurally related to rifaximin (Xifaxan),
another minimally absorbed oral ...
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.
Drugs for Cardiac Arrhythmias
Treatment Guidelines from The Medical Letter • Jun 01, 2007 (Issue 58)
q12h; pediatric dosage should be 6.6-13.3
mg/kg q8h or 15 mg/kg q12h.
3) p. 48: Xifaxan ...
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.